Login to Your Account



Europe's second gene therapy, GSK's Strimvelis, clears regulatory hurdle

By Nuala Moran
Staff Writer

Tuesday, April 5, 2016

LONDON – The EMA has given the nod to Glaxosmithkline plc's (GSK) Strimvelis, the second gene therapy to get regulatory endorsement in Europe and the first such product to offer an effective cure for an inherited disorder following one-off treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription